TY - JOUR
T1 - Unraveling the epigenetic code of cancer for therapy
AU - Smith, Laura T.
AU - Otterson, Gregory A.
AU - Plass, Christoph
N1 - Funding Information:
The authors wish to thank Bjoern Hackanson and Martin Brena for critical discussions of the manuscript. Financial support was obtained for L.T.S by a T32 CA009338–28 fellowship in Oncology, P30-CA16058, PO1-CA101956–01 (CP), The Leukemia and Lymphoma Society of America. C.P is a Leukemia and Lymphoma Society Scholar.
PY - 2007/9
Y1 - 2007/9
N2 - Alterations in the genome and the epigenome are common in most cancers. Changes in epigenetic signatures, including aberrant DNA methylation and histone deacetylation, are among the most prevalent modifications in cancer and lead to dramatic changes in gene expression patterns. Because DNA methylation and histone deacetylation are reversible processes, they have become attractive as targets for cancer epigenetic therapy, both as single agents and as 'enhancing' agents for other treatment strategies. In this review we discuss our current view of the mammalian epigenome, this view has changed over the years because of the availability of novel technologies. We further demonstrate how the profound understanding of epigenetic alterations in cancer will help develop novel strategies for epigenetic therapies.
AB - Alterations in the genome and the epigenome are common in most cancers. Changes in epigenetic signatures, including aberrant DNA methylation and histone deacetylation, are among the most prevalent modifications in cancer and lead to dramatic changes in gene expression patterns. Because DNA methylation and histone deacetylation are reversible processes, they have become attractive as targets for cancer epigenetic therapy, both as single agents and as 'enhancing' agents for other treatment strategies. In this review we discuss our current view of the mammalian epigenome, this view has changed over the years because of the availability of novel technologies. We further demonstrate how the profound understanding of epigenetic alterations in cancer will help develop novel strategies for epigenetic therapies.
UR - https://www.scopus.com/pages/publications/34547914473
U2 - 10.1016/j.tig.2007.07.005
DO - 10.1016/j.tig.2007.07.005
M3 - Review article
C2 - 17681396
AN - SCOPUS:34547914473
SN - 0168-9525
VL - 23
SP - 449
EP - 456
JO - Trends in Genetics
JF - Trends in Genetics
IS - 9
ER -